Robeco Institutional Asset Management B.V. Buys 26,980 Shares of Alkermes plc (NASDAQ:ALKS)

Robeco Institutional Asset Management B.V. grew its stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 28.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 122,489 shares of the company's stock after purchasing an additional 26,980 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.08% of Alkermes worth $3,523,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALKS. Loomis Sayles & Co. L P grew its position in shares of Alkermes by 365.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock worth $52,704,000 after buying an additional 1,478,422 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Alkermes in the third quarter worth $16,126,000. Barclays PLC boosted its holdings in Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company's stock valued at $11,867,000 after acquiring an additional 220,893 shares in the last quarter. Edgestream Partners L.P. increased its position in Alkermes by 218.4% during the 3rd quarter. Edgestream Partners L.P. now owns 270,671 shares of the company's stock valued at $7,576,000 after purchasing an additional 185,648 shares during the period. Finally, HealthInvest Partners AB raised its holdings in Alkermes by 243.9% in the 3rd quarter. HealthInvest Partners AB now owns 236,610 shares of the company's stock worth $6,623,000 after purchasing an additional 167,810 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors.

Alkermes Stock Down 0.3 %

Shares of NASDAQ:ALKS traded down $0.08 on Thursday, hitting $31.39. 1,468,272 shares of the company traded hands, compared to its average volume of 1,393,782. The stock has a 50 day simple moving average of $29.98 and a 200-day simple moving average of $28.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company has a market cap of $5.08 billion, a PE ratio of 16.10, a PEG ratio of 1.68 and a beta of 0.49. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $32.88.

Insider Activity at Alkermes

In other news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total transaction of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares of the company's stock, valued at $1,769,492.45. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 238,185 shares of company stock valued at $7,498,117. 4.89% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALKS. HC Wainwright reaffirmed a "neutral" rating and set a $37.00 target price on shares of Alkermes in a research note on Friday, October 25th. Mizuho lifted their price objective on Alkermes from $35.00 to $40.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Stifel Nicolaus raised Alkermes from a "hold" rating to a "buy" rating and increased their target price for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. The Goldman Sachs Group dropped their price target on Alkermes from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $36.00.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.